Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma
Carregando...
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
Citação
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.31, n.2, p.333-336, 2017
Resumo
Background Erythroderma is a clinical skin syndrome shared by patients with cutaneous disorders of distinct aetiologies as a result of the combined actions of chemokines, adhesion molecules, and cytokines, such as vascular endothelial growth factor (VEGF). Objective To evaluate the profile of serum levels of VEGF and soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) in pemphigus foliaceus (PF) patients with erythroderma. Methods We conducted a retrospective study, which included (i) a chart review of all PF patients from the Autoimmune Blistering Clinic, University of Sao Paulo, Brazil, from January 1991 to December 2014, together with an evaluation of demographic variables, hospitalization duration and complications and (ii) analysis of the circulating VEGF and sVEGFR-1 levels in PF patients with erythroderma by ELISA. The controls included patients with pemphigus vulgaris or psoriasis. Results We observed higher serum VEGF levels in PF patients during erythroderma than during the non-erythrodermic phase. PF patients showed increased serum levels of sVEGFR-1 during the erythrodermic phase in comparison to controls. Interestingly, the sVEGFR-1 and antidesmoglein-1 levels were positively correlated during the non-erythrodermic period. Conclusion Erythroderma, which represents one clinical form of PF, implies more severe outcomes. The circulating levels of VEGF, a potent endothelial activator, are increased in PF patients with erythroderma; this result suggests the contribution of the blood vessel endothelium to the pathogenesis of this clinical syndrome. Interestingly, our findings showed a positive correlation between the sVEGFR-1 and antidesmoglein-1 antibody levels, indicating a suppressive response to VEGF augmentation during the erythrodermic phase of PF.
Palavras-chave
Referências
- Ameglio F, 1997, J BIOL REG HOMEOS AG, V11, P148
- Bae ON, 2015, BIOMOL THER, V23, P12, DOI 10.4062/biomolther.2014.102
- BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974
- Creamer D, 1996, LANCET, V348, P1101, DOI 10.1016/S0140-6736(05)64447-9
- Elias PM, 2008, AM J PATHOL, V173, P689, DOI 10.2353/ajpath.2008.080088
- Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
- Flisiak I, 2010, CYTOKINE, V52, P225, DOI 10.1016/j.cyto.2010.09.012
- James KA, 2011, DERMATOL CLIN, V29, P405, DOI 10.1016/j.det.2011.03.012
- Joly P, 2011, CLIN DERMATOL, V29, P432, DOI 10.1016/j.clindermatol.2011.01.013
- Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964
- Lehman JS, 2011, DERMATOL CLIN, V29, P591, DOI 10.1016/j.det.2011.06.021
- Ozmen A, 2016, BIOTECH HISTOCHEM, V91, P296, DOI 10.3109/10520295.2016.1161234
- Pal S, 1998, INT J DERMATOL, V37, P104
- Ruffini F, 2011, BRIT J DERMATOL, V164, P1061, DOI 10.1111/j.1365-2133.2010.10200.x
- Samorano-Lima LD, 2014, INT J DERMATOL, V53, P685, DOI 10.1111/j.1365-4632.2012.05818.x
- Sehgal VN, 2004, INT J DERMATOL, V43, P39, DOI 10.1111/j.1365-4632.2004.01975.x
- Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
- Sigurdsson V, 2000, J CUTAN PATHOL, V27, P436, DOI 10.1034/j.1600-0560.2000.027009436.x
- Weiss D, 2015, ACTA DERM-VENEREOL, V95, P559, DOI 10.2340/00015555-2023
- Yang KY, 2011, CRIT CARE, V15, DOI 10.1186/cc9412